Early Intervention to Prevent Lower Limb Lymphedema of Gynecological Malignancy

Inclusion Criteria: 1.Gynecologic oncology patients undergoing radiotherapy after lymph node surgery who voluntarily participate in this study and sign an informed consent form. 2.18 to 60 years old. 3.Eastern Cooperative Oncology Group（ECOG) score less than 2. 4.Expected survival time greater than 3 years. 5.Hemoglobin(Hb) greater than or equal to 70 g/L, white blood cells (WBC)greater than or equal to 3.5 × 109 /L, neutrophils(ANC)greater than or equal to 1.5 × 109 /L, platelets (PLT)greater than or equal to 80 × 109 /L. 6.serum alamine aminotransferase(ALT) and glutamic oxalacetic transaminase(AST) less than 2 times the normal value and creatinine less than 1.5 times the normal value, albumin greater than or equal to 35g/L. 7.Women of childbearing potential must have had a pregnancy test (serum or urine) within 7 days prior to enrollment and have a negative result and be willing to use an appropriate method of contraception for the duration of the trial. 8.Ability to comply with the trial protocol, as judged by the investigator. Exclusion Criteria: 1. Lymphedema and deep vein thrombosis of the lower extremities were clearly diagnosed; 2. Acute infection of any kind; 3. Patients with lower extremity edema; 4. pregnancy, menstrual period; 5. Recent major abdominal surgery (determined by the investigator); 6. Radiation colitis, cystitis, intestinal infection, small bowel or large bowel diverticulitis or diverticulitis; 7. Liver fibrosis; 8. Abdominal aortic aneurysm; 9. acute phlebitis; 10. Severe arterial obstructive disease, arterial ulcer, ABPI (ankle-brachial blood pressure index) greater than 1.3 and less than 0.5; 11. Severe peripheral neuropathy; 12. Poor control of hypertension, poor control of stroke and diabetes, and severe bronchial asthma; 13. Patients who cannot understand the experimental content and cannot cooperate and those who refuse to sign the informed consent; 14. Those with concomitant diseases or other special circumstances that seriously endanger the patient's safety or affect the patient's completion of the study.